PBH Stock — Prestige Consumer Healthcare Inc.

Up next

Next earnings call

Feb 4, 2027 Est · unconfirmed · in 12 wks

Q1 2027 earnings call transcript

call held Aug 6, 2026

Play latest call

Latest documents

what the company just published, in one sentence each

2026

Nov 5

Quarterly report 10-Q FY2027 Q2, ended Sep 30

Revenue rises 22.7% as gross margin falls to 51.3%

Prestige Consumer Healthcare reported revenue growth of 22.7% for the three months ended September 30, 2026, but gross margin fell to 51.3% from 55.3%. Interest expense rose to $30.0 million, while outstanding indebtedness reached $2.1 billion as September 30, 2026.

Revenue $336.31M ▲ 22.7% Net income $25.3M ▼ 40.1% Diluted EPS $0.53 ▼ 38.4%

Read from the MD&A section

4 source passages

Total revenues for the three months ended September 30, 2026 were $336.3 million, an increase of $62.2 million, or 22.7%, versus the three months ended September 30, 2025. As a percentage of total revenues, gross profit decreased to 51.3% during three months ended September 30, 2026 from 55.3% during three months ended September 30, 2025, primarily due to costs associated with improving and optimizing the acquired Pillar5 facility for increases in long-term capacity, and amortization of inventory fair value step-up related to the acquisitions of the OTC Wellness Business and LaCorium Health. Interest expense, net was $30.0 million during the three months ended September 30, 2026 versus $10.0 million during the three months ended September 30, 2025. As of September 30, 2026, we had an aggregate of $2.1 billion of outstanding indebtedness, which consisted of the following: Open the document at this passage

Nov 5

Current report 8-K

Revenue rises 22.7%, but Clear Eyes constraints cut outlook

Prestige Consumer Healthcare Inc. reported Q2 revenue of $336.3 million, up 22.7%, and adjusted diluted EPS of $1.13. Fiscal 2027 guidance fell to $1,280 to $1,290 million revenue and $4.48 to $4.55 adjusted diluted EPS due to Clear Eyes production variability at Pillar5.

Financial results, Regulation FD disclosure Read from the first part of this long document

5 source passages

Prestige Consumer Healthcare Inc. Reports Fiscal 2027 Second Quarter Results Q2 Revenue of $336.3 million, up 22.7% versus prior year Q2 Diluted EPS of $0.53; Adjusted Diluted EPS of $1.13, compared to prior year Adjusted Diluted EPS of $1.07 Adjusting guidance outlook range to $1,280 to $1,290 million in revenue, $4.48 to $4.55 in Adjusted Diluted EPS We are updating our fiscal 2027 outlook for revenues to $1,280 million to $1,290 million and adjusted diluted EPS of $4.48 to $4.55 primarily to reflect recent variability in Clear Eyes® production at Pillar5, which is expected to reduce product availability and revenue in the second half. Open the document at this passage

Sep 10

Investor event

Barclays Annual Global Consumer Conference AI summary on its way

Aug 14

Current report 8-K Events of Aug 10

Director or officer change, or executive pay AI summary on its way

Aug 12

Investor event

Canaccord Genuity 46th Annual Growth Conference AI summary on its way

All documents

Metrics snapshot

Useful current figures from the complete screener profile.

View all 125 metrics

Revenue (TTM)

$1.17B

Trailing 12 months

Net income (TTM)

$155.10M

Trailing 12 months

Revenue growth YoY

+22.7%

Year over year

Operating margin

25.0%

Trailing 12 months

P / E (TTM)

14.3

Trailing earnings · reciprocal yield 7.0%

FCF yield

9.8%

TTM · current market cap

Return on invested capital

—

Trailing 12 months

Net cash

−$1.93B

Latest balance sheet

Dividend yield

—

Trailing 12 months

Shares change YoY

-3.4%

Year over year · fewer shares

Price change (1Y)

-23.0%

Trailing year

Short interest

9.0%

Latest settlement · 8.1 days to cover

View all 125 metrics

Quarterly results

Revenue Net income Net loss

▲2.7% $290.32M $61.03M '25 Q3 ▲7% $296.52M $50.13M '25 Q4* ▼6.6% $249.53M $47.47M '26 Q1 ▼3.4% $274.11M $42.21M '26 Q2 ▼2.4% $283.44M $46.70M '26 Q3 ▼5% $281.62M $53.93M '26 Q4* ▲6.5% $265.71M $29.18M '27 Q1 LATEST ▲22.7% $336.31M $25.30M '27 Q2

* Q4 derived as the full year minus Q1 to Q3.

Equibles Rating

blended score · not investment advice

Overall

Sell

SellHoldBuy

Technical Sell Momentum Very Weak Sentiment Neutral Fundamentals Strong Quant / Vol High

Market backdrop VIX 19.3 · elevated Equity put/call 0.63

Technical

price trend

Sell

50 / 200-day cross No cross

Price vs 200-day avg −13%

below

Price vs 50-day avg −3%

below

RSI (14) 47

neutral

MACD trend Negative

52-week position 12%

near low

Momentum

relative strength

Very Weak

1-month return −7%

trailing

6-month return −4%

trailing

YTD return −25%

this year

Relative strength −4%

vs S&P · 6-mo

Sentiment

smart money

Neutral

Trend (MA cross) No cross

50d $47 › 200d $53 — 200d above 50d

Institutional flow Accumulating

302 of 320 funds reported for Sep 30 · net +846.6K sh shares · +53 new

Insider flow Flat

No net insider activity over 90 days

Short interest Rising

8.95% of shares out · ▲ +7.1% MoM · 8.1 days cover

Volume signal Normal

Volume near normal

Institution breadth Steady

320 holders — mid 3-yr range

Squeeze score 72

high risk · 0–100

Fundamentals

Strong

Revenue growth +37%

Y/Y

Gross margin 61%

contracting

EPS growth −9%

Y/Y

Free cash flow $246.4M

Valuation P/E 14.3

below peers

Buyback $92.2M

remaining

Balance sheet $930.1M

net debt

Quant / Vol

risk profile

High

Volatility 38%

annualized · 1-yr

Max drawdown −39%

past year

ATR 4.3%

of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Guidance & track record

what management promised — and delivered

Beat or met 4 of last 8

Latest guidance · from the Earnings Call filed Aug 6, 2026

Fiscal 27

Organic revenue growth Non-GAAP Maintained 1% – 3%

May 13, 2026 1% – 3% Aug 6, 2026 1% – 3%

Adjusted diluted EPS Non-GAAP Raised $4.55 – $4.65

May 14, 2026 $4.42 – $4.51 Aug 6, 2026 $4.55 – $4.65

Adjusted free cash flow Non-GAAP at least $270M

the second quarter

Revenue $328M – $331M

prior qtr $336.31M midpoint −2.0% QoQ

second quarter

Adjusted diluted EPS Non-GAAP $1.06 – $1.08

Revenue $328M – $331M

both Q2 and the full year

Adjusted gross margin Non-GAAP 57%

the full year

Adjusted G&A Non-GAAP 10%

fiscal 27, as well as Q2

A&M rate Non-GAAP 14.5%

Previous outlook earlier release · from the 8-K filed May 13, 2026

Still-open targets the latest release did not restate under the same label.

Free Cash Flow · Fiscal 2027 at least $250M

Revenue growth · next three years 10%

EPS growth · next three years 8%

EBITDA · once the business is fully integrated $12M

Free cash flow · next three years $900M

Adjusted free cash flow · fiscal 2027 at least $250M

EBITDA including the benefits from anticipated synergies · once the business is fully integrated $12M

Revenue growth · Over this period 10%

EPS growth CAGR · Over this period 8%

Marketing · FY 27 at least 13%

EPS CAGR · over the next three years 8%

Revenue growth CAGR · over the next three years 10%

Total Free Cash Flow · over next three years $900M

Guided vs delivered · last 8 settled

Revenue the second quarter

guided $328M – $331M

guided $328M – $331M $336.31M Beat +2.1%

Revenue Q1

guided $250M

guided $250M $265.71M Beat +6.3%

Sales outlook fiscal 26

guided $1.1B

guided $1.1B $1.09B Miss −1.0%

GAAP Diluted EPS FY'26

guided $4.16

guided $4.16 $3.91 Miss −6.0%

Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.

Technicals

trend & momentum for long-term holders Sell

3 · 3 · 0

50 / 200-day cross

No cross Neutral

Price vs 200-day avg

−13% Bearish

Price vs 50-day avg

−3% Neutral

RSI (14)

47 Neutral

MACD trend

Negative Bearish

52-week position

12% Bearish

Market signals — smart money & positioning

Mixed

Trend (MA cross) No cross

50d $47 › 200d $53 — 200d above 50d

Institutional flow Accumulating

302 of 320 funds reported for Sep 30 · net +846.6K sh shares · +53 new

Insider flow Flat

No net insider activity over 90 days

Short interest Rising

8.95% of shares out · ▲ +7.1% MoM · 8.1 days cover

Volume signal Normal

Volume near normal

Institution breadth Steady

320 holders — mid 3-yr range

Price context

position in its 52-week range

Range low $43 Now $46 · 12% Range high $70

vs 200-day avg -13% vs 50-day avg -3%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

the company's own KPIs, from written earnings releases and filings

Metric	Latest	Period	YoY
Contribution Margin	$120.31M	FY2027 Q2	+6.6%

Adjusted Diluted EPS non-GAAP	$0.98	Q1 fiscal 2027	+0.0%

Adjusted EBITDA non-GAAP	$84.1M	Q1 FY 27	—

Adjusted EBITDA Margin non-GAAP	31.6%	Q1 FY 27	—
Adjusted Gross Margin non-GAAP	55%	Q1 FY 27	—
Adjusted Non-GAAP Free Cash Flow non-GAAP	$83.7M	Q1 fiscal 2027	—

GAAP → non-GAAP reconciliation Non-GAAP Free Cash Flow 67.09M (the result of another reconciliation in this filing) +16.66M Acquisition and other costs paid = Non-GAAP Adjusted Free Cash Flow 83.75M
Non-GAAP Adjusted General and Administrative Expense non-GAAP	30.48M	Three Months Ended June 30, 2026	—
GAAP → non-GAAP reconciliation GAAP GAAP General and Administrative Expense 28.46M +0K Costs associated with acquisition (a) = Non-GAAP Adjusted General and Administrative Expense 28.46M
Non-GAAP Adjusted Gross Margin non-GAAP	146.18M	Three Months Ended June 30, 2026	—
GAAP → non-GAAP reconciliation GAAP GAAP Gross Profit 140.33M +0K Amortization of inventory fair value step-up +0K Acquired facility remediation, period overhead and idle capacity costs (a) = Non-GAAP Adjusted Gross Margin 140.33M
Non-GAAP Adjusted Net Income non-GAAP	46.5M	Three Months Ended June 30, 2026	+0.0%

GAAP → non-GAAP reconciliation GAAP GAAP Net Income 29.18M +2.84M Amortization of inventory fair value step-up +70K Depreciation of idle assets during remediation period (a) +7.15M Acquired facility remediation, period overhead and idle capacity costs (b) +12.82M Costs associated with acquisition in General and Administrative Expense (c) -5.56M Tax impact of adjustments (d) = Non-GAAP Adjusted Net Income 46.5M
Non-GAAP EBITDA non-GAAP	61.24M	Three Months Ended June 30, 2026	—
GAAP → non-GAAP reconciliation GAAP GAAP Net Income 47.47M +10.2M Interest expense, net +14.31M Provision for income taxes +7.67M Depreciation and amortization = Non-GAAP EBITDA 79.65M
Non-GAAP Free Cash Flow non-GAAP	67.09M	Three Months Ended June 30, 2026	+0.0%

GAAP → non-GAAP reconciliation GAAP GAAP Net cash provided by operating activities 70.79M -3.7M Purchases of property and equipment = Non-GAAP Free Cash Flow 67.09M
Non-GAAP Organic Revenues non-GAAP	259.77M	Three Months Ended June 30, 2026	+0.0%

GAAP → non-GAAP reconciliation GAAP GAAP Total Revenues 265.71M -5.95M Revenues associated with acquisition (a) +0K Impact of foreign currency exchange rates = Non-GAAP Organic Revenues 259.77M
Organic sales growth non-GAAP	3.2%	Q1 fiscal 2027	+0.0%

Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period

Versus peers

Drug Manufacturers - Specialty & Generic — same industry group

Open screener →

Company	Mkt cap	YTD	Rev growth Y/Y	P/E	Short % shares
PBH Prestige Consumer Healthcare Inc. this stock	$2.19B	-25.1%	-4.3%	14.3	9.0%
TAK Takeda Pharmaceutical Co Ltd	$68.47B	+37.5%	—	—	0.1%
GALDY Galderma Group AG	$53.23B	+10.1%	—	—	0.0%
TEVA Teva Pharmaceutical Industries Ltd	$51.92B	+42.6%	+4.3%	101.1	2.4%
JHPCY Jiangsu Hengrui Pharmaceuticals Co., Ltd.	$40.66B	—	—	—	0.0%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section

Ownership

Institutional Holders Accumulating

Holders

340

% held: 115.2%
Reported: 302 of 320
Top holder: BlackRock, Inc.

Held Float

View

Held by Funds

Fund positions

349

View

Short & Settlement

Short Interest Rising

Shares short

4.2M

Days to cover: 8.1d
Change: +281.1K sh

View

Short Volume

Short vol %

62%

As of: Nov 13, 2026

Short Total

View

Fails to Deliver

FTD shares

1

Value: $49
As of: Oct 14, 2026

View

Off-Exchange

Off-exchange %

40.9%

Week of: Oct 5, 2026

Off-exch Lit

View

Financials

Revenue (FY)

$1.1B

Net income (FY): $190.3M
EPS diluted: $3.91

View

Buybacks

Authorized

$300.0M

Remaining: $92.2M

Spent Remaining

View

Filings

SEC Filings

Latest

10-Q

Filed: Nov 5, 2026
This year: 22

Prestige Consumer Healthcare reported revenue growth of 22.7% for the three months ended September 30, 2026, but gross margin fell to 51.3% from 55.3%. Interest expense rose to $30.0 million, while outstanding indebtedness reached $2.1 billion as September 30, 2026.

View

Proposed Sales

Value

$18.4K

Shares: 351
Filed: May 11, 2026

View

Earnings & Events

Webcasts

Last webcast

Nov 5, 2026

View

Investor Relations

	5D	20D	120D	MTD	YTD
PBH	+7.5%	-7.5%	-3.8%	-5.9%	-25.1%
SPY	+2.6%	-1.2%	+0.5%	-0.2%	+10.6%
vs SPY	+4.9%	-6.3%	-4.3%	-5.7%	-35.8%

PBH · Prestige Consumer Healthcare Inc.

Price & Indicators

Up next

Latest documents

Metrics snapshot

Quarterly results

Equibles Rating

Guidance & track record

Technicals

Key metrics

Versus peers

At a glance

Performance

Capital returns